U.S. Food and Drug Administration, Center for Drug Evaluation and Research
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.
Mindenképp látogasd meg a podcast oldalát, és támogasd a készítőjét: www.fda.gov
Szerző
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Kategória
A podcast weboldala
Legutóbbi epizód
2025. jan. 17.
Hol hallgathatod?
Podcastok az alkalmazásban Replaio Radio HamarosanA podcastok hamarosan megérkeznek az alkalmazásba. Telepítsd most, és láss elsőként egy teljesen új megközelítést a podcastokhoz
Telepítsd ingyen
Android közel 10 M letöltés · 4,8-as értékelés
iOS hamarosan
Epizódok
FDA D.I.S.C.O. Burst Edition: FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma 16.02.2023 6:29
Listen to a soundcast of the January 19, 2023, FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer 23.01.2023 6:59
Listen to a soundcast of the December 9 and 12, 2022, FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer”
FDA D.I.S.C.O. Burst Edition: FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors 20.01.2023 3:30
Listen to a soundcast of the December 16, 2022, FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
FDA D.I.S.C.O. Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy 19.01.2023 3:30
Listen to a soundcast of the December 22, 2022, FDA approval of Lunsumio (mosunetuzumab-axgb) for ipatients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.”
FDA D.I.S.C.O. Burst Edition: FDA approves updated drug labeling including new indications and dosing regimens for Xeloda (capecitabine) tablets under Project Renewal 17.01.2023 4:00
Listen to a soundcast of the December 14, 2022, FDA approval of Xeloda (capecitabine) under Project Renewal, an initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date.
FDA D.I.S.C.O. Burst Edition: FDA approval of Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation 10.01.2023 3:30
Listen to a soundcast of the December 1, 2022, FDA approval of Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.
FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer 06.01.2023 4:00
FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
Hasonló podcastok
Hallgasd a(z) FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) podcastot a Replaióban
Rádió és podcastok egy alkalmazásban - ingyen és regisztráció nélkül. Telepítsd még ma, és ne maradj le a premierről
A Replaio nem podcastkiadó; a műsorok nevei, borítóképei és hanganyagai a szerzőiket illetik, és nyilvános RSS-csatornákon keresztül terjednek.
